Rapid digital patient-derived organoid testing for guiding therapy in patients with metastatic breast cancer receiving antibody drug conjugates (ADCs).
Randomized trial develops a digital organoid assay to guide treatment in metastatic breast cancer, suggesting new precision therapy opportunities.
Key Points
The study aims to create a diagnostic tool using digital patient-derived organoids to guide treatment decisions in metastatic breast cancer patients after antibody drug conjugate therapy.
Prospective collection of fresh tumor biopsies from metastatic breast cancer patients receiving ADC therapy.
Drug sensitivity assays using digital patient-derived organoids with ADCs and chemotherapy agents.
Correlation analysis with clinical outcomes utilizing progression free survival as a metric.
DPO establishment success rate was 64.71%, with variation by breast cancer subtype: 100% in HER2+, 73% in TNBC, and 56% in HR+HER2- BC.
Prior exposure to ADCs reduced DPO sensitivity, indicating acquired resistance, especially in heavily treated patients.
DPOs often remained responsive to alternative agents, offering new treatment avenues in the context of ADC resistance.